HARRINGTON PARK, N.J.--(BUSINESS WIRE)-- United Water announced today that Lisette Provencher, senior vice president, operations support, for United Water, has been elected to serve on the Board of Governors of the World Water Council. Bernard Guirkinger, Senior Executive Vice President of United Waters parent company SUEZ ENVIRONNEMENT was elected as an Alternate Representative for Ms. Provencher. The World Water Council, representing some 350 organizations in more than 70 countries, works to ensure water security. Ms. Provencher is one of 36 governors, drawn from 13 countries and six international and intergovernmental organizations. She was elected by majority vote from among 64 candidates and will serve until 2015, when the World Water Forum, an international triennial gathering, next convenes. Ms. Provencher succeeds Patrick Cairo, senior vice president, corporate development, of United Water, who served on the Board of Governors of the World Water Council for six years. The elections took place in November during the councils general assembly for which 240 participants had gathered in Marseille, France. Having focused during the past three years on increasing awareness, fostering dialogue and encouraging the emergence of solutions, the World Water Council is now moving forward in three strategic directions: water security for human essential … Continue reading →

EXTON, Pa.--(BUSINESS WIRE)-- BioTrends Research Group, one of the worlds leading research and advisory firms for specialized biopharmaceutical issues, finds that Novartiss Gilenya captures 5.4 percent of those multiple sclerosis (MS) patients treated with disease-modifying agents (DMAs) in the EU5 (France, Germany, Italy, Spain, and the U.K.). This represents an increase from 2.3 percent share one year ago, with significant growth seen among relapsing remitting MS (RRMS), primary relapsing MS (PRMS) and secondary progressive MS (SPMS) patient segments. Consistent with this growth in patient share, neurologists rate their overall satisfaction with Gilenya and its performance on efficacy-related attributes, such as relapse rate reduction, long-term, sustained efficacy and clinical data support, significantly higher compared to 2011. However, it is important to highlight that neurologists rate Biogen Idec/lans Tysabri significantly higher on overall satisfaction and performance than all other commercially available DMAs, likely due to positive perceptions of Tysabris performance on efficacy-related attributes. TreatmentTrends: Multiple Sclerosis (EU) 2012 report also finds that the greatest percent of neurologists continue to voice a first-line preference for Biogen Idecs Avonex or a high dose/high frequency interferon (Merck Seronos Rebif for RRMS and Bayers Betaferon for progressive MS). However, compared to 2011, significantly more neurologists report … Continue reading →